On March 19, 2024 Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, reported that preclinical data and clinical trial design from the study of SON-080 (recombinant human Interleukin-6 or rhIL-6) in CIPN will be presented in a poster session at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, to be held April 5-10, in San Diego, California (Press release, Sonnet BioTherapeutics, MAR 19, 2024, View Source [SID1234641271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Title: Low dose interleukin-6 (SON-080) for neuropathies: Toxicology and clinical plans

Session Title: Pharmacology and Pharmacogenetics

Presentation Type: Poster

Session Date and Time: Wednesday April 10, 2024, 9:00 AM – 12:30 PM

Abstract Number: 7181

Location: Poster Section 24

Poster Board Number: 22